Clinical Trials
6 trialsNCT04385290 2025-09-08
MOSAIC
Technische Universität Dresden
Phase 1/2 Recruiting
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT03760445 2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2 Withdrawn
NCT01202877 2018-10-16
PKC412 and 5-Azacytidine
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00045942 2017-08-11
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
Novartis
Phase 1/2 Completed
NCT00866281 2015-12-22
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Novartis
Phase 1/2 Terminated